3-氯-4-甲基-1,8-二氮杂萘 | 893566-38-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 3-氯-4-甲基-1,8-二氮杂萘
• 英文名称: 3-chloro-4-methyl[1,8]naphthyridine
• 英文别名: 3-Chloro-4-methyl-1,8-naphthyridine
• CAS: 893566-38-6
• 化学式: C₉H₇ClN₂
• 分子量: 178.621
• InChiKey: DCFDZTDFUHLKOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-氯-4-甲基-1,8-二氮杂萘 在 selenium(IV) oxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 3.0h， 以26%的产率得到3-chloro-1,8-naphthyridine-4-carbaldehyde
  参考文献：
  名称：

  Discovery of Azetidinyl Ketolides for the Treatment of Susceptible and Multidrug Resistant Community-Acquired Respiratory Tract Infections

  摘要：

  Respiratory tract bacterial strains are becoming increasingly resistant to currently marketed macrolide antibiotics. The current alternative telithromycin (1) from the newer ketolide class of macrolides addresses resistance but is hampered by serious safety concerns, hepatotoxicity in particular. We have discovered a novel series of azetidinyl ketolides that focus on mitigation of hepatotoxicity by minimizing hepatic turnover and time-dependent inactivation of CYP3A isoforms in the liver without compromising the potency and efficacy of 1.

  DOI：

  10.1021/jm900729s
• 作为产物：
  描述：

  N-(5-chloro-4-methylpyridin-2-yl)pivalamide 、 3-二甲氨基丙烯醛 在 叔丁基锂 作用下， 以 乙醚 为溶剂， 以52%的产率得到3-氯-4-甲基-1,8-二氮杂萘
  参考文献：
  名称：

  Discovery of Azetidinyl Ketolides for the Treatment of Susceptible and Multidrug Resistant Community-Acquired Respiratory Tract Infections

  摘要：

  Respiratory tract bacterial strains are becoming increasingly resistant to currently marketed macrolide antibiotics. The current alternative telithromycin (1) from the newer ketolide class of macrolides addresses resistance but is hampered by serious safety concerns, hepatotoxicity in particular. We have discovered a novel series of azetidinyl ketolides that focus on mitigation of hepatotoxicity by minimizing hepatic turnover and time-dependent inactivation of CYP3A isoforms in the liver without compromising the potency and efficacy of 1.

  DOI：

  10.1021/jm900729s

文献信息

• Macrolides
  申请人：Chupak S. Louis

  公开号：US20060135447A1

  公开（公告）日：2006-06-22

  Macrolide compounds per se, as shown below and defined herein, and their use, e.g., as antibacterial and antiprotozoal agents in animals, including humans: Also disclosed are methods of preparing the compounds, intermediates, and pharmaceutical compositions thereof, and methods of treating or preventing disease by administering the compounds to subjects in need. This abstract is only an excerpt and is not limiting of the invention.

  本发明涉及以下Macrolide化合物及其定义，以及它们在动物中，包括人类中作为抗菌和抗原虫剂的用途：还公开了制备这些化合物、中间体和药物组成物的方法，以及通过将这些化合物用于需要的主体治疗或预防疾病的方法。此摘要仅为摘录，不限制本发明。
• MACROLIDES
  申请人：Pfizer Products Incorporated

  公开号：EP1836211A1

  公开（公告）日：2007-09-26
• US7462600B2
  申请人：——

  公开号：US7462600B2

  公开（公告）日：2008-12-09
• [EN] MACROLIDES<br/>[FR] MACROLIDES
  申请人：PFIZER PROD INC

  公开号：WO2006067589A1

  公开（公告）日：2006-06-29

  [EN] Macrolide compounds per se, as shown below and defined herein, and their use, e.g., as antibacterial and antiprotozoal agents in animals, including humans: Formula (I). Also disclosed are methods of preparing the compounds, intermediates, and pharmaceutical compositions thereof, and methods of treating or preventing disease by administering the compounds to subjects in need. This abstract is only an excerpt and is not limiting of the invention.
  [FR] La présente invention concerne des composés macrolides représentés ci-dessous par la formule (I), et définis dans l'invention, et leur utilisation, par ex. en tant qu'agents antibactériens et agents antiprotozoaires chez des animaux, y compris chez les êtres humains. L'invention a également pour objet des procédés pour préparer des composés, des intermédiaires, et des compositions pharmaceutiques correspondantes, ainsi que des procédés pour traiter ou prévenir des maladies par administration des composés à des personnes qui en ont besoin. L'invention ne se limite pas à ce qui est décrit dans cet abrégé qui ne représente qu'une partie de l'invention.
• Discovery of Azetidinyl Ketolides for the Treatment of Susceptible and Multidrug Resistant Community-Acquired Respiratory Tract Infections
  作者：Thomas V. Magee、Sharon L. Ripp、Bryan Li、Richard A. Buzon、Lou Chupak、Thomas J. Dougherty、Steven M. Finegan、Dennis Girard、Anne E. Hagen、Michael J. Falcone、Kathleen A. Farley、Karl Granskog、Joel R. Hardink、Michael D. Huband、Barbara J. Kamicker、Takushi Kaneko、Michael J. Knickerbocker、Jennifer L. Liras、Andrea Marra、Ivy Medina、Thuy-Trinh Nguyen、Mark C. Noe、R. Scott Obach、John P. O’Donnell、Joseph B. Penzien、Usa Datta Reilly、John R. Schafer、Yue Shen、Gregory G. Stone、Timothy J. Strelevitz、Jianmin Sun、Amelia Tait-Kamradt、Alfin D. N. Vaz、David A. Whipple、Daniel W. Widlicka、Donn G. Wishka、Joanna P. Wolkowski、Mark E. Flanagan

  DOI：10.1021/jm900729s

  日期：2009.12.10

  Respiratory tract bacterial strains are becoming increasingly resistant to currently marketed macrolide antibiotics. The current alternative telithromycin (1) from the newer ketolide class of macrolides addresses resistance but is hampered by serious safety concerns, hepatotoxicity in particular. We have discovered a novel series of azetidinyl ketolides that focus on mitigation of hepatotoxicity by minimizing hepatic turnover and time-dependent inactivation of CYP3A isoforms in the liver without compromising the potency and efficacy of 1.